Literature DB >> 22737269

Increased wild-type N-ras activation by neurofibromin down-regulation increases human neuroblastoma stem cell malignancy.

Dan Han1, Barbara A Spengler, Robert A Ross.   

Abstract

Cellular heterogeneity is a well-known feature of human neuroblastoma tumors and cell lines. Of the 3 phenotypes (N-, I-, and S-type) isolated and characterized, the I-type cancer stem cell of neuroblastoma is the most malignant. Here, we report that, although wild-type N-Ras protein is expressed at the same level in all 3 neuroblastoma cell phenotypes, activated N-Ras-GTP level is significantly higher in I-type cancer stem cells. When activated N-Ras levels were decreased by transfection of a dominant-negative N-Ras construct, the malignant potential of I-type cancer stem cells decreased significantly. Conversely, when weakly malignant N-type cells were transfected with a constitutively active N-Ras construct, activated N-Ras levels, and malignant potential, were significantly increased. Thus, high levels of N-Ras-GTP are required for the increased malignancy of I-type neuroblastoma cancer stem cells. Moreover, increased activation of N-Ras results from significant down-regulation of neurofibromin (NF1), an important RasGAP. This specific down-regulation is mediated by an ubiquitin-proteasome-dependent pathway. Thus, decreased expression of NF1 in I-type neuroblastoma cancer stem cells causes a high level of activated N-Ras that is, at least in part, responsible for their higher tumorigenic potential.

Entities:  

Keywords:  N-Ras; malignancy; neuroblastoma cancer stem cell; neurofibromin

Year:  2011        PMID: 22737269      PMCID: PMC3379567          DOI: 10.1177/1947601912443127

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  32 in total

1.  Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras.

Authors:  M Tsuneoka; E Mekada
Journal:  Oncogene       Date:  2000-01-06       Impact factor: 9.867

Review 2.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

3.  NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

Authors:  Michael Hölzel; Sidong Huang; Jan Koster; Ingrid Ora; Arjan Lakeman; Huib Caron; Wouter Nijkamp; Jing Xie; Tom Callens; Shahab Asgharzadeh; Robert C Seeger; Ludwine Messiaen; Rogier Versteeg; René Bernards
Journal:  Cell       Date:  2010-07-23       Impact factor: 41.582

4.  Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.

Authors:  B A Spengler; D L Lazarova; R A Ross; J L Biedler
Journal:  Oncol Res       Date:  1997       Impact factor: 5.574

5.  Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.

Authors:  V Ciccarone; B A Spengler; M B Meyers; J L Biedler; R A Ross
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

6.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

7.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

Authors:  Lauren T McGillicuddy; Jody A Fromm; Pablo E Hollstein; Sara Kubek; Rameen Beroukhim; Thomas De Raedt; Bryan W Johnson; Sybil M G Williams; Phioanh Nghiemphu; Linda M Liau; Tim F Cloughesy; Paul S Mischel; Annabel Parret; Jeanette Seiler; Gerd Moldenhauer; Klaus Scheffzek; Anat O Stemmer-Rachamimov; Charles L Sawyers; Cameron Brennan; Ludwine Messiaen; Ingo K Mellinghoff; Karen Cichowski
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

8.  Contrasting levels of p21ras activation and expression of neurofibromin in peripheral primitive neuroectodermal tumour and neuroblastoma cells, and their response to retinoic acid.

Authors:  S A Burchill; P A Berry; F M Bradbury; I J Lewis
Journal:  J Neurol Sci       Date:  1998-05-07       Impact factor: 3.181

9.  Regulation of the Ras-GTPase activating protein neurofibromin by C-tail phosphorylation: implications for protein kinase C/Ras/extracellular signal-regulated kinase 1/2 pathway signaling and neuronal differentiation.

Authors:  George Leondaritis; Loizos Petrikkos; Dimitra Mangoura
Journal:  J Neurochem       Date:  2009-02-11       Impact factor: 5.372

10.  Human neuroblastoma I-type cells are malignant neural crest stem cells.

Authors:  R A Ross; B A Spengler; C Domènech; M Porubcin; W J Rettig; J L Biedler
Journal:  Cell Growth Differ       Date:  1995-04
View more
  3 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma.

Authors:  Gabriella Cunha Vieira; S Chockalingam; Zsombor Melegh; Alexander Greenhough; Sally Malik; Marianna Szemes; Ji Hyun Park; Abderrahmane Kaidi; Li Zhou; Daniel Catchpoole; Rhys Morgan; David O Bates; Peter David Gabb; Karim Malik
Journal:  Oncotarget       Date:  2015-11-24

3.  Genotype-Phenotype Correlations in Neurofibromatosis Type 1: Identification of Novel and Recurrent NF1 Gene Variants and Correlations with Neurocognitive Phenotype.

Authors:  Filomena Napolitano; Milena Dell'Aquila; Chiara Terracciano; Giuseppina Franzese; Maria Teresa Gentile; Giulio Piluso; Claudia Santoro; Davide Colavito; Anna Patanè; Paolo De Blasiis; Simone Sampaolo; Simona Paladino; Mariarosa Anna Beatrice Melone
Journal:  Genes (Basel)       Date:  2022-06-23       Impact factor: 4.141

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.